Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
ABUS

ABUS - Arbutus Biopharma Corp Stock Price, Fair Value and News

$4.14-0.02 (-0.48%)
Market Closed

8/100

ABUS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

8/100

ABUS

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$3.25

Target 3M

$3.65

Target 6M

$3.45

ABUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABUS Price Action

Last 30 days

-12.3%

Last 90 days

-14.5%

Trailing 12 Months

23.6%

ABUS RSI Chart

ABUS Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

ABUS Valuation

Market Cap

796.2M

Price/Earnings (Trailing)

-18.83

Price/Sales (Trailing)

54.51

EV/EBITDA

-12.14

Price/Free Cashflow

-17.55

ABUS Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$3.25

Target 3M

$3.65

Target 6M

$3.45

ABUS Fundamentals

ABUS Revenue

Revenue (TTM)

14.6M

Rev. Growth (Yr)

-60.49%

Rev. Growth (Qtr)

-95.07%

ABUS Earnings

Earnings (TTM)

-42.3M

Earnings Growth (Yr)

60.73%

Earnings Growth (Qtr)

-406.86%

ABUS Profitability

EBT Margin

-486.81%

Return on Equity

-54.62%

Return on Assets

-43.27%

Free Cashflow Yield

-5.7%

ABUS Investor Care

Shares Dilution (1Y)

1.49%

Diluted EPS (TTM)

-0.23

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20256.4M15.4M14.6M0
202413.0M10.1M6.7M6.2M
202333.1M23.5M22.2M18.1M
202221.5M33.4M36.0M39.0M
20217.5M8.4M10.2M11.0M
20206.2M6.5M6.7M6.9M
20195.2M4.6M9.5M6.0M
201811.9M12.1M6.8M5.9M
20173.8M6.1M8.4M10.7M
201619.0M13.2M7.3M1.5M
201515.2M16.8M16.5M24.9M
201417.8M16.7M18.1M15.0M
201317.9M17.1M16.3M15.5M
201217.1M17.5M17.9M18.3M
201120.2M19.0M17.8M16.6M
Get all data in R, Python etc through our Historical Stock Data APIs

About Arbutus Biopharma Corp

ABUS
Arbutus Biopharma Corporation, a biopharmaceutical company, develops novel therapeutics for chronic Hepatitis B virus (HBV) infection, SARS-CoV-2, and other coronaviruses in the United States. Its HBV product pipeline consists of AB-729, a proprietary subcutaneously-delivered RNAi therapeutic product candidate that suppresses all HBV antigens, including HBsAg expression. The company's research and development programs include AB-161, an oral HBV RNA destabilizer; AB-101, an oral PD-L1 inhibitor to reawaken patients' HBV-specific immune system; and small molecule antiviral medicines to treat coronaviruses, including COVID-19. It has licensing agreements with Gritstone Oncology, Inc; Alnylam Pharmaceuticals, Inc.; Qilu Pharmaceuticals Co, Ltd; Assembly Biosciences, Inc.; Acuitas Therapeutics, Inc.; and Antios Therapeutics, Inc. Arbutus Biopharma Corporation also has a clinical collaboration agreement with Vaccitech plc to evaluate AB-729. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.
 CEO
 WEBSITEarbutusbio.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES96

Arbutus Biopharma Corp Frequently Asked Questions

ABUS is the stock ticker symbol of Arbutus Biopharma Corp. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Arbutus Biopharma Corp is 796.22 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check ABUS's fair value in chart for subscribers.

The fair value guage provides a quick view whether ABUS is over valued or under valued. Whether Arbutus Biopharma Corp is cheap or expensive depends on the assumptions which impact Arbutus Biopharma Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for ABUS.

As of Wed Jan 28 2026, ABUS's PE ratio (Price to Earnings) is -18.83 and Price to Sales (PS) ratio is 54.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. ABUS PE ratio will change depending on the future growth rate expectations of investors.

In the past 10 years, Arbutus Biopharma Corp has provided 0.028 (multiply by 100 for percentage) rate of return.